The EURORDIS Summer School on Medicines Research & Development is made up of one week of face-to-face training, held in June in Barcelona, and the training modules below, which are available for anyone to use for free.
The EURORDIS Summer School aims to provide rare disease patient advocates with the knowledge and skills needed to become experts in medicines research and development. Since 2015, researchers are also welcome to attend the Summer School.
Over 20 experts, from across all rare disease stakeholders, deliver the training each year. The topics covered include clinical trials methodology, clinical research, ethics in medicines development, regulatory affairs, health technology assessment and marketing authorisation.
The first edition of the EURORDIS Summer School took place in June 2008, in Barcelona.
Next Summer School training
The next edition of the EURORDIS Summer School will take place 6-10 June 2022 in Barcelona.
APPLY NOW to the EURORDIS Summer School 2022. Click here to open the application form. The deadline for applications is 15 November 2021.
Ahead of the online training week, participants take part in 3 pre-training webinars and complete a selection of the online courses listed below.
Take part in free online training
Learn more about medicines research and development at a time and place that suits you! Take the free e-learning courses below.
The conditions of use for all EURORDIS e-learning courses have been licensed with Creative Commons. More information on the conditions of use.
Before you start, you may want to download the following Glossary document, which covers key terms in that you will find in the different courses below:
[▼] Glossary on Methodology, Ethics, Statistics, Pharmacology and Regulation
We also advise you to download this compilation elaborated by the European Medicines Agency (EMA) containing plain-language descriptions of medical terms commonly used in information about medicines:
[▼] EMA Medical Terms Simplifier
To date, more than 400 participants from over 40 countries representing more than 75 diseases have participated in the EURORDIS Summer School.
Thanks to capacity-building provided by EURORDIS, alumni members have gone on to become involved in various activities at the European Medicines Agency (EMA), such as Protocol Assistance, and to participate in activities related to the European Network for Health Technology Assessment (EUnetHTA).
Summer School alumni report an increased awareness of the importance of their involvement in all aspects of medicines development and of their potential to be a real force at European and national level.
History of the EURORDIS Summer School
The Summer School was originally developed to fill specific needs identified by expert patients, EURORDIS and the European Medicines Agency.
Expert patients from EURORDIS are permanent representatives on EMA Scientific Committees and working parties, for example, the Committee for Orphan Medicinal Products, the Patients’ and Consumers’ Working Partyand the Scientific Advice Working Party.
EURORDIS therefore created the Summer School in recognition of patients’ need for support and training that includes an overview of clinical research and methodology, medicines development and regulatory procedures.
The EURORDIS Summer School 2021 has received funding under an operating grant from the European Union’s Health Programme (2014-2020) and under the European Union’s Horizon 2020 Research and Innovation Programme, notably under the HTx project (grant agreement Nº 825162) and under the European Joint Programme on Rare Diseases (grant agreement N°825575).